CorMedix, Inc. (AMEX:CRMD), Polus BioPharm Inc. (KOSE:A007630) By The Numbers: Investor Review

Placing CorMedix, Inc. (AMEX:CRMD) shares under the microscope we note that the firm has a current Return on Equity of -5.437779.  Simply put, this ratio determines how well the firm uses investment funds to generate profit.  This ratio is often considered “the mother of all ratios” as it often reveals how well a company is operating.

Investors will be trying to gauge which way stock market momentum will shift as we head into the close of the calendar year. Some may be of the mindset that the bears will be taking over shortly. Others may be super bullish and ready for the market to make a further run higher. Trying to predict which way the tide will shift is no easy task. Being prepared for any situation that arises is a god way to combat the uncertainty that always follows the market. Being prepared can help the investor make quick, tough decisions when the time comes. Many investors may have already figured out that holding onto losers for too long can be damaging for the portfolio. They may have also realized that holding onto winners too long can also have negative effects. Finding that perfect buy/sell balance can end up being the difference between a good portfolio and a great one.

In additiona to ROE, investors might also take into consideration some other ratios.  One of the most popular ratios is the “Return on Assets” (aka ROA).  This score indicates how profitable a company is relative to its total assets.  The Return on Assets for CorMedix, Inc. (AMEX:CRMD) is -1.994202.  This number is calculated by dividing net income after tax by the company’s total assets.  A company that manages their assets well will have a higher return, while a company that manages their assets poorly will have a lower return.

The Return on Invested Capital (aka ROIC) for CorMedix, Inc. (AMEX:CRMD) is -3.388924.  The Return on Invested Capital is a ratio that determines whether a company is profitable or not.  It tells investors how well a company is turning their capital into profits.  The ROIC is calculated by dividing the net operating profit (or EBIT) by the employed capital.  The employed capital is calculated by subrating current liabilities from total assets.  Similarly, the Return on Invested Capital Quality ratio is a tool in evaluating the quality of a company’s ROIC over the course of five years.  The ROIC Quality of CorMedix, Inc. (AMEX:CRMD) is -1.142158.  This is calculated by dividing the five year average ROIC by the Standard Deviation of the 5 year ROIC.  The ROIC 5 year average is calculated using the five year average EBIT, five year average (net working capital and net fixed assets).  The ROIC 5 year average of CorMedix, Inc. (AMEX:CRMD) is -5.207703.

After a recent scan, we can see that CorMedix, Inc. (AMEX:CRMD) has a Shareholder Yield of -0.500440 and a Shareholder Yield (Mebane Faber) of -0.48491. The first value is calculated by adding the dividend yield to the percentage of repurchased shares. The second value adds in the net debt repaid yield to the calculation. Shareholder yield has the ability to show how much money the firm is giving back to shareholders via a few different avenues. Companies may issue new shares and buy back their own shares. This may occur at the same time. Investors may also use shareholder yield to gauge a baseline rate of return.

Quant Scores

Checking in on some valuation rankings, CorMedix, Inc. (AMEX:CRMD) has a Value Composite score of 97. Developed by James O’Shaughnessy, the VC score uses five valuation ratios. These ratios are price to earnings, price to cash flow, EBITDA to EV, price to book value, and price to sales. The VC is displayed as a number between 1 and 100. In general, a company with a score closer to 0 would be seen as undervalued, and a score closer to 100 would indicate an overvalued company. Adding a sixth ratio, shareholder yield, we can view the Value Composite 2 score which is currently sitting at 98.

Investors may be interested in viewing the Gross Margin score on shares of CorMedix, Inc. (AMEX:CRMD). The name currently has a score of 65.00000. This score is derived from the Gross Margin (Marx) stability and growth over the previous eight years. The Gross Margin score lands on a scale from 1 to 100 where a score of 1 would be considered positive, and a score of 100 would be seen as negative.

CorMedix, Inc. (AMEX:CRMD) has a current MF Rank of 17106. Developed by hedge fund manager Joel Greenblatt, the intention of the formula is to spot high quality companies that are trading at an attractive price. The formula uses ROIC and earnings yield ratios to find quality, undervalued stocks. In general, companies with the lowest combined rank may be the higher quality picks.

CorMedix, Inc. (AMEX:CRMD) has a current ERP5 Rank of 17767. The ERP5 Rank may assist investors with spotting companies that are undervalued. This ranking uses four ratios. These ratios are Earnings Yield, ROIC, Price to Book, and 5 year average ROIC. When looking at the ERP5 ranking, it is generally considered the lower the value, the better.

Price Index & Volatility

Stock volatility is a percentage that indicates whether a stock is a desirable purchase.  Investors look at the Volatility 12m to determine if a company has a low volatility percentage or not over the course of a year.  The Volatility 12m of CorMedix, Inc. (AMEX:CRMD) is 150.014700.  This is calculated by taking weekly log normal returns and standard deviation of the share price over one year annualized.  The lower the number, a company is thought to have low volatility.  The Volatility 3m is a similar percentage determined by the daily log normal returns and standard deviation of the share price over 3 months.  The Volatility 3m of CorMedix, Inc. (AMEX:CRMD) is 117.379000.  The Volatility 6m is the same, except measured over the course of six months.  The Volatility 6m is 129.017800.

As soon as an individual decides what they want out of their investments, they can start formulating the best way to accomplish those goals. The time horizon for each investor may be different. Fluctuations in the financial markets can have a big effect on shorter-term investments. Investors that need a certain amount of money in a shorter amount of time may be looking to develop a stock market strategy with a bit less risk involved. On the other end of the spectrum, a younger investor with a longer time horizon might be able to search for stocks with a higher potential for growth that may involve much more risk. The volatility of today’s markets can test the nerves of any investor. Understanding volatility and market fluctuations can help the investor gauge their risk tolerance in the markets.

We can now take a quick look at some historical stock price index data. CorMedix, Inc. (AMEX:CRMD) presently has a 10 month price index of 6.30418. The price index is calculated by dividing the current share price by the share price ten months ago. A ratio over one indicates an increase in share price over the period. A ratio lower than one shows that the price has decreased over that time period. Looking at some alternate time periods, the 12 month price index is 7.82814, the 24 month is 1.39328, and the 36 month is 0.39196. Narrowing in a bit closer, the 5 month price index is 1.38167, the 3 month is 0.89140, and the 1 month is currently 1.04937.

In reviewing some key ratios and quant data for Polus BioPharm Inc. (KOSE:A007630), we note that the mother of all ratios (Return on Equity) stands at -0.628870 for the firm.  ROE reveals what percentage of each investment dollar is returned as a profit.  Used in conjunction with a variety of other ratios, this indicator is a very important tool for investors in determining the effectiveness of a company to generate returns for investors.

Individual investors often strive to create a solid strategy before trying to take on the market. Setting up realistic, attainable goals, may be a good place for the amateur to start. There are many different approaches that the investor can take when getting into the stock market. Some investors will try to follow strategies that have worked for others in the past. Sometimes this will work, and sometimes it will not. Markets and economic landscapes are constantly changing. A strategy that worked yesterday may not work again tomorrow. Investors who put in the time to do the necessary homework may find themselves much better off when the market decides to rear its ugly head at some point down the road. 

Further, we can look at some other ratios and financial indicators in order to get an idea of the company’s valuation.  Polus BioPharm Inc. (KOSE:A007630) presently has a current ratio of 0.05. The current ratio, also known as the working capital ratio, is a liquidity ratio that displays the proportion of current assets of a business relative to the current liabilities. The ratio is simply calculated by dividing current liabilities by current assets. The ratio may be used to provide an idea of the ability of a certain company to pay back its liabilities with assets. Typically, the higher the current ratio the better, as the company may be more capable of paying back its obligations.

The FCF Yield 5yr Average is calculated by taking the five year average free cash flow of a company, and dividing it by the current enterprise value.  Enterprise Value is calculated by taking the market capitalization plus debt, minority interest and preferred shares, minus total cash and cash equivalents.  The average FCF of a company is determined by looking at the cash generated by operations of the company.  The Free Cash Flow Yield 5 Year Average of Polus BioPharm Inc. (KOSE:A007630) is -0.014890. 

One of the most popular ratios is the “Return on Assets” (aka ROA).  This score indicates how profitable a company is relative to its total assets.  The Return on Assets for Polus BioPharm Inc. (KOSE:A007630) is -0.444141.  This number is calculated by dividing net income after tax by the company’s total assets.  A company that manages their assets well will have a higher return, while a company that manages their assets poorly will have a lower return.

The M-Score, conceived by accounting professor Messod Beneish, is a model for detecting whether a company has manipulated their earnings numbers or not. Polus BioPharm Inc. (KOSE:A007630) has an M-Score of -4.589673.  The M-Score is based on 8 different variables: Days’ sales in receivables index, Gross Margin Index, Asset Quality Index, Sales Growth Index, Depreciation Index, Sales, General and Administrative expenses Index, Leverage Index and Total Accruals to Total Assets.  A score higher than -1.78 is an indicator that the company might be manipulating their numbers.

The Value Composite One (VC1) is a method that investors use to determine a company’s value.  The VC1 of Polus BioPharm Inc. (KOSE:A007630) is 88.  A company with a value of 0 is thought to be an undervalued company, while a company with a value of 100 is considered an overvalued company.  The VC1 is calculated using the price to book value, price to sales, EBITDA to EV, price to cash flow, and price to earnings.  Similarly, the Value Composite Two (VC2) is calculated with the same ratios, but adds the Shareholder Yield.  The Value Composite Two of Polus BioPharm Inc. (KOSE:A007630) is 92.

The MF Rank (aka the Magic Formula) is a formula that pinpoints a valuable company trading at a good price.  The formula is calculated by looking at companies that have a high earnings yield as well as a high return on invested capital.  The MF Rank of Polus BioPharm Inc. (KOSE:A007630) is 13107.  A company with a low rank is considered a good company to invest in.  The Magic Formula was introduced in a book written by Joel Greenblatt, entitled, “The Little Book that Beats the Market”.

The Earnings to Price yield of Polus BioPharm Inc. KOSE:A007630 is -0.251128.  This is calculated by taking the earnings per share and dividing it by the last closing share price.  This is one of the most popular methods investors use to evaluate a company’s financial performance.  Earnings Yield is calculated by taking the operating income or earnings before interest and taxes (EBIT) and dividing it by the Enterprise Value of the company.  The Earnings Yield for Polus BioPharm Inc. KOSE:A007630 is -0.045054.  Earnings Yield helps investors measure the return on investment for a given company.  Similarly, the Earnings Yield Five Year Average is the five year average operating income or EBIT divided by the current enterprise value.  The Earnings Yield Five Year average for Polus BioPharm Inc. (KOSE:A007630) is -0.011917.

Price Index

The Price Index is a ratio that indicates the return of a share price over a past period. The price index of Polus BioPharm Inc. (KOSE:A007630) for last month was 0.91486. This is calculated by taking the current share price and dividing by the share price one month ago. If the ratio is greater than 1, then that means there has been an increase in price over the month. If the ratio is less than 1, then we can determine that there has been a decrease in price. Similarly, investors look up the share price over 12 month periods. The Price Index 12m for Polus BioPharm Inc. (KOSE:A007630) is 0.16946.

Price Range 52 Weeks

Some of the best financial predictions are formed by using a variety of financial tools. The Price Range 52 Weeks is one of the tools that investors use to determine the lowest and highest price at which a stock has traded in the previous 52 weeks. The Price Range of Polus BioPharm Inc. (KOSE:A007630) over the past 52 weeks is 0.126000. The 52-week range can be found in the stock’s quote summary.

Stock market knowledge can be highly powerful. Successful investors are often highly knowledgeable and have put in the appropriate amount of time to become this way. Proper stock market knowledge may take a long time to acquire. Investors may spend countless hours trying to get an edge, and they may still feel like they are swimming upstream. Preparation and common sense can be highly important when trying to stay on top of the equity market. These days, there is no shortage of information for investors to get their hands on. The challenge then becomes how best to use the information at hand in order to develop knowledge that will help drive profits higher.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.